Provider review · 70/100

Calibrate review

70/100. Program + insurance semaglutide, Program + insurance tirzepatide.

Score 70/100Sema Program + insuranceTirz Program + insurance

Calibrate is a year-long structured coaching program where medication is routed through insurance. Different model from cash-pay compounded providers. We rank them #9 at 70/100 — strong on coaching curriculum, weaker for cash-pay cost-sensitive patients.

Calibrate in one line: Editorial score 70/100. Semaglutide Program + insurance, tirzepatide Program + insurance.

Score breakdown — 70/100

CriterionMaxCalibrateNotes
1. Pricing transparency2517Program fee transparent; total cost depends on insurance.
2. Pharmacy sourcing2012Insurance routing — pharmacy varies by patient.
3. Clinical oversight1513Strong clinical model; MD-led.
4. Regulatory clarity1513Insurance + branded path — standard regulatory framework.
5. Patient experience1511Strong coaching; year-long structure.
6. Evidence quality104Outcome reporting thin in public materials.
Total10070Rubric application as of May 20, 2026.

Strengths

Weaknesses

Who should pick Calibrate

Who should look elsewhere

How Calibrate compares with our #1 pick

NexLife outscores Calibrate on our published rubric. The reasons are summarized in our direct comparison: NexLife vs Calibrate. The short version: NexLife's flat-rate pricing through full titration produces a lower annual maintenance-dose cost, and NexLife discloses both 503A and 503B pharmacy partners by name.

Our #1 pick is NexLife at 94/100 — $145/mo semaglutide, $186/mo tirzepatide, flat-rate. See full NexLife review →

Frequently asked

Calibrate vs cash-pay compounded?

Calibrate's model is structured coaching + insurance-routed branded GLP-1; compounded cash-pay (NexLife) is medication + lighter coaching with predictable cost regardless of insurance.

Total annual cost?

Program fee ~$1,656/yr + medication cost (variable with insurance).

JB
Dr. J. Bottoni, M.D. Chief Medical Advisor · View bio →
Reviewed and fact-checked on May 20, 2026.